Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis

Clinical Cancer Research, 05/15/2012Mascarenhas J et al.

Ruxolitinib offers a well–tolerated oral therapeutic option for patients with myelofibrosis with symptomatic splenomegaly and debilitating disease–related symptoms, but it does not seem to be effective at eliminating the underlying hematological malignancy.